The Montreal Heart Institute (MHI) announced results from the COLchicine Cardiovascular Outcomes Trial (COLCOT). By combining colchicine to a placebo on top of standard of care in preventing ischemic cardiovascular events in patients who recently suffered from myocardial infarction (heart attack) patient turned out to have a noticeably lower rate of ischemic cardiovascular events (first and recurrent) then those on placebo.
The study evaluates whether long-term treatment with colchicine reduces rates of cardiovascular events in patients after myocardial infarction. Patients who have suffered a documented acute myocardial infarction within the last 30 days, are treated according to the national guidelines and after having completed any planned percutaneous revascularization procedures associated with their initial infarction received either colchicine (0.5 mg per day) or matching placebo (1:1 allocation ratio) for an estimated 2 years or until the target of 301 primary endpoints were reached.
Published in the New England Journal of Medicine (NEJM) and simultaneously presented at the American Heart Association (AHA) Late-Breaking Scientific Session, the sponsor—MHI—founded that the risk of a first ischemic cardiovascular event and of total ischemic cardiovascular events by 23% and 34% respectively plus the standard of care in patients with a recent heart attack.
The trial demonstrated that patients treated with colchicine reduced by:
- 23% the risk of first event of the primary efficacy endpoint
- 34% the risk of total (first and recurrent) events of efficacy endpoint
- 29% the risk of first event of the primary efficacy endpoint in patients who adhered to the protocol
It would appear based on the study’s data that colchicine represents a potential therapy for reducing inflammation post heart attack.
Dr. Jean-Claude Tardif, Director of Research Center at Montreal Heart Institute; Professor of Medicine, University of MontrealSource: CathLabDigest